Valsartan

Overview

Valsartan, sold under the brand name Diovan among others, is an oral medication used to treat high blood pressure, heart failure, and diabetic kidney disease. It is an angiotensin II receptor blocker (ARB). It is a reasonable initial treatment for high blood pressure.[1] WP

Common side effects include feeling tired, dizziness, high blood potassium, diarrhea, and joint pain. Other serious side effects may include kidney problems, low blood pressure, and angioedema. Use in pregnancy may harm the baby and use when breastfeeding is not recommended. It is an angiotensin II receptor antagonist and works by blocking the effects of angiotensin II.[1][2] WP

Valsartan was patented in 1990, and came into medical use in 1996. It is available as a generic medication. In 2023, it was the 85th most commonly prescribed medication in the United States, with more than 7 million prescriptions.[3–6] WP

Uses, dosage and effects

Medical uses

Valsartan is used to treat high blood pressure, heart failure, and to reduce death for people with left ventricular dysfunction after having a heart attack.[7][8] WP

High blood pressure

Valsartan (and other ARBs) are an appropriate initial treatment option for most people with high blood pressure and no other coexisting conditions, as are ACE inhibitors, thiazide diuretics and calcium channel blockers. If patients have coexisting diabetes or kidney disease, ARBs or ACE inhibitors may be considered over other classes of blood pressure medicines.[9][10][11] WP

Heart failure

Valsartan has reduced rates of mortality and heart failure hospitalisations when used alone or in combination with beta blockers in the treatment of heart failure. Importantly, the combination of valsartan and ACE inhibitors has not shown morbidity or mortality benefits but rather increases mortality risk when added to combination beta blocker and ACE inhibitor therapy, and increases the risk of adverse events like hyperkalaemia, hypotension and renal failure. As shown in the PARADIGM-HF study, valsartan combined with sacubitril for the treatment of heart failure, significantly reduced all cause and cardiovascular mortality and hospitalisations due to heart failure.[12][13][14] WP

Diabetic kidney disease

In people with type 2 diabetes, antihypertensive therapy with valsartan decreases the rate of progression of albuminuria (albumin in urine), promotes regression to normoalbuminuria and may reduce the rate of progression to end-stage kidney disease.[15][16][17] WP

Risks and side effects

Contraindications

The packaging for valsartan includes a warning stating the drug should not be used with the renin inhibitor aliskiren in people with diabetes. It also states the safety of the drug in severe renal impairment has not been established.[8] WP

Valsartan includes a black box warning for fetal toxicity. Discontinuation of these agents is recommended immediately after detection of pregnancy and an alternative medication should be started. Breastfeeding is not recommended.[2][8][18][19] WP

Side effects

Side effects depend on the reason the medication is being used. WP

Heart failure

Adverse effects are based on a comparison versus placebo in people with heart failure. Most common side effects include dizziness (17% vs 9%), low blood pressure (7% vs 2%), and diarrhea (5% vs 4%). Less common side effects include joint pain, fatigue, and back pain (all 3% vs 2%).[8] WP

Hypertension

Clinical trials for valsartan treatment for hypertension versus placebo demonstrate side effects like viral infection (3% vs 2%), fatigue (2% vs 1%) and abdominal pain (2% vs 1%). Minor side effects that occurred at >1% but were similar to rates from the placebo group include:[8] WP

• headache[8] WP
• dizziness[8] WP
• upper respiratory infection[8] WP
• cough[8] WP
• diarrhea[8] WP
• rhinitis/sinusitis[8] WP
• nausea[8] WP
• pharyngitis[8] WP
• edema[8] WP
• arthralgia[8] WP

Kidney failure

People treated with ARBs including valsartan or diuretics are susceptible to conditions of developing low renal blood flow such as abnormal narrowing of blood vessels in the kidney, hypertension, renal artery stenosis, heart failure, chronic kidney disease, severe congestive heart failure, or volume depletion whose renal function is in part dependent on the activity of the renin-angiotensin system like efferent arteriolar vasoconstriction done by angiotensin II are at high risk of deterioration of renal function comprising acute kidney failure, oliguria, worsening azotemia or heightened serum creatinine. When blood flow to the kidneys is reduced, the kidney activates a series of responses that triggers angiotensin release to constrict blood vessels and facilitate blood flow in the kidney. So long as the nephron function degradation is progressive or reaches clinically significant levels, withholding or discontinuing valsartan is warranted.[8][20–23] WP

Interactions

Interactions

The US prescribing information lists the following drug interactions for valsartan: WP

• Other inhibitors of the renin-angiotensin system may increase the risks of low blood pressure, kidney problems, and hyperkalemia. WP⚠ Wikipedia itself has flagged this text: citation needed.
• Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium may increase the risk of hyperkalemia. WP⚠ Wikipedia itself has flagged this text: citation needed.
• NSAIDs may increase the risk of kidney problems and may interfere with blood pressure-lowering effects. WP⚠ Wikipedia itself has flagged this text: citation needed.
• Valsartan may increase the concentration of lithium.[8] WP
• Valsartan and other angiotensin-related blood pressure medications may interact with the antibiotics co-trimoxazole or ciprofloxacin to increase risk of sudden death due to cardiac arrest.[24] WP

Food interaction

With the tablet, food decreases the valsartan tablet taker's exposure to valsartan by about 40% and peak plasma concentration (Cmax) by about 50%, evidenced by AUC change.[8] WP

Pharmacology

Pharmacodynamics

Valsartan blocks the actions of angiotensin II, which include constricting blood vessels and activating aldosterone, to reduce blood pressure. The drug binds to angiotensin type I receptors (AT1), working as an antagonist. This mechanism of action is different than that of the ACE inhibitor drugs, which block the conversion of angiotensin I to angiotensin II. As valsartan acts at the receptor, it can provide more complete angiotensin II antagonism since angiotensin II is generated by other enzymes as well as ACE. Also, valsartan does not affect the metabolism of bradykinin like ACE inhibitors do.[25][26] WP

Pharmacokinetics

The peak concentration of valsartan in plasma occurs 2 to 4 hours after dosing. AUC and Cmax values of valsartan are observed to be approximately linearly dose-dependent over therapeutic dosing range. Owing to its relatively short elimination half life attribution, valsartan concentration in plasma does not accumulate in response to repeated dosing.[8] WP

Research

Research

In people with impaired glucose tolerance, valsartan may decrease the incidence of developing diabetes mellitus type 2. However, the absolute risk reduction is small (less than 1 percent per year) and diet, exercise or other drugs, may be more protective. In the same study, no reduction in the rate of cardiovascular events (including death) was shown.[27] WP

In one study of people without diabetes, valsartan reduced the risk of developing diabetes mellitus over amlodipine, mainly for those with hypertension.[28] WP

A prospective study demonstrated a reduction in the incidence and progression of Alzheimer's disease and dementia.[29] WP

Legal status

Economics

In 2010, valsartan (trade name Diovan) achieved annual sales of $2.052 billion in the United States and $6.053 billion worldwide. The patents for valsartan and valsartan/hydrochlorothiazide expired in September 2012.[30][31][32] WP

Combinations

Versions are available as the combinations valsartan/hydrochlorothiazide, valsartan/amlodipine, valsartan/amlodipine/hydrochlorothiazide, valsartan/nebivolol, and valsartan/sacubitril.[1][33–37] WP

Valsartan is combined with amlodipine or hydrochlorothiazide (HCTZ) (or both) into single-pill formulations for treating hypertension with multiple drugs.[1][38][39][40] WP

Valsartan is also available as the combination valsartan/sacubitril. It is used to treat heart failure with reduced ejection fraction.[37][41][42][43] WP

Recalls

In July 2018, the European Medicines Agency (EMA) recalled certain batches of valsartan and valsartan/hydrochlorothiazide film-coated tablets distributed in 22 countries in the European Union. Zhejiang Huahai Pharmaceutical Co. (ZHP) in Linhai, China manufactured the bulk ingredient contaminated by N-nitrosodimethylamine (NDMA), a carcinogen. The active pharmaceutical ingredient was subsequently imported by a number of generic drugmakers, including Novartis, and marketed in Europe and Asia under their subsidiary Sandoz labeling, and in the UK by Dexcel Pharma Ltd and Accord Healthcare.[44][45] WP

Valsartan was recalled in Canada. Authorities believe the degree of contamination is negligible. In July 2018, The National Agency of Drug and Food Control (NA-DFC or Badan POM Indonesia) announced voluntary recalls for two products containing valsartan produced by Actavis Indonesia and Dipa Pharmalab Intersains. In July 2018, the US Food and Drug Administration (FDA) announced voluntary recalls of certain supplies of valsartan and valsartan/hydrochlorothiazide in the US distributed by Solco Healthcare LLC, Major Pharmaceuticals, and Teva Pharmaceutical Industries. Hong Kong's Department of Health initiated a similar recall. In August 2018, the FDA published two lengthy, updated lists, classifying hundreds of specific US products containing valsartan into those included versus excluded from the recall. A week later, the FDA cited two more drugmakers, Zhejiang Tianyu Pharmaceuticals of China and Hetero Labs Limited of India, as additional sources of the contaminated valsartan ingredient.[45–54] WP

In September 2018, the FDA announced that retesting of all valsartan supplies had found a second carcinogenic impurity, N-nitrosodiethylamine (NDEA), in the recalled products made by ZHP in China and marketed in the US under the Torrent Pharmaceuticals (India) brand.[55] WP

According to a 2018 Reuters analysis of national medicines agencies' records, more than 50 companies around the world have recalled valsartan mono-preparations or combination products manufactured from the tainted valsartan ingredient. The contamination has likely been present since 2012 when the manufacturing process was changed and approved by EDQM and FDA authorities. Based on inspections in late 2018, both agencies have suspended the Chinese and Indian manufacturers' certificates of suitability for the supply of valsartan in the EU and the US.[56] WP

In 2019, many more preparations of valsartan and its combinations were recalled due to the presence of the contaminant NDMA.[57][58] WP

In August 2020, the European Medicines Agency (EMA) provided guidance to marketing authorization holders on how to avoid the presence of nitrosamine impurities in human medicines and asked them to review all chemical and biological human medicines for the possible presence of nitrosamines and to test the products at risk.[59] WP

The FDA issued revised guidelines about nitrosamine impurities in September 2024.[60] WP

Shortages

Since July 2018, numerous recalls of losartan, valsartan and irbesartan drug products have caused marked shortages of these life-saving medications in North America and Europe, particularly for valsartan. In March 2019, the FDA approved an additional generic version of valsartan to address the issue. According to the agency, the shortage of valsartan was resolved in April 2020, but the availability of the generic form remained unstable into July 2020. Pharmacies in the European Union were notified that the supply of the drug, particularly for higher dosage forms, would remain unstable well into December 2020.[61][62][63] WP

Chemistry

Formula

C24H29N5O3 PC

CAS number

137862-53-4 PC

Molar mass (g/mol)

435.5 PC

IUPAC name (computed by PubChem)

(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid PC

SMILES

CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O PC

InChIKey

ACWBQPMHZXGDFX-QFIPXVFZSA-N PC

PubChem CID

60846

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Valsartan Monograph for Professionals
2. Other Valsartan Pregnancy and Breastfeeding Warnings
3. Other Analogue-based Drug Discovery. 2006
4. Other British national formulary: BNF 76. 2018
5. Other Top 300 of 2023
6. Other Valsartan Drug Usage Statistics, United States, 2014 - 2023
7. Other Randa HD. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 2011
8. Journal / agency Diovan- valsartan tablet. 12 June 2019
9. Journal / agency Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. March 2016. doi:10.1016/s0140-6736(15)01225-8 · PMID 26724178
10. Journal / agency Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The New England Journal of Medicine. September 2001. doi:10.1056/nejmoa011161 · PMID 11565518
11. Journal / agency Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Rydén L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal. July 2013. doi:10.1093/eurheartj/eht151 · PMID 23771844
12. Journal / agency Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. The New England Journal of Medicine. December 2001. doi:10.1056/NEJMoa010713 · PMID 11759645
13. Journal / agency Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ. January 2013. doi:10.1136/bmj.f360 · PMID 23358488 · PMC3556933
14. Journal / agency McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin-neprilysin inhibition versus enalapril in heart failure. The New England Journal of Medicine. September 2014. doi:10.1056/NEJMoa1409077 · PMID 25176015
15. Journal / agency Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. August 2002. doi:10.1161/01.CIR.0000024416.33113.0A · PMID 12163426
16. Journal / agency Galle J, Schwedhelm E, Pinnetti S, Böger RH, Wanner C. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrology, Dialysis, Transplantation. October 2008. doi:10.1093/ndt/gfn230 · PMID 18450829
17. Journal / agency Hollenberg NK, Parving HH, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, Kandra A, Daley WL, Rocha R. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. Journal of Hypertension. September 2007. doi:10.1097/HJH.0b013e328277596e · PMID 17762658
18. Other Diovan Product Monograph
19. Other Product Monograph - PrDIOVAN® (valsartan). 12 May 2015
20. Other Kumar A, Fausto A. Pathologic Basis of Disease. 2010
21. Journal / agency Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. November 2011. doi:10.1161/cir.0b013e318235eb4d · PMID 22052934
22. Other KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. January 2013
23. Journal / agency Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. Seminars in Dialysis. 7 June 2007. doi:10.1111/j.1525-139x.2007.00280.x · PMID 17555487
24. Journal / agency Fralick M, Macdonald EM, Gomes T, Antoniou T, Hollands S, Mamdani MM, Juurlink DN. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ. October 2014. doi:10.1136/bmj.g6196 · PMID 25359996 · PMC4214638
25. Other Katzung BG, Trevor AJ. Basic & Clinical Pharmacology. 2015
26. Journal / agency Unger T. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?. The American Journal of Cardiology. November 1999. doi:10.1016/s0002-9149(99)00728-6 · PMID 10588089
27. Journal / agency McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM. Effect of valsartan on the incidence of diabetes and cardiovascular events. The New England Journal of Medicine. April 2010. doi:10.1056/NEJMoa1001121 · PMID 20228403
28. Journal / agency Kjeldsen SE, McInnes GT, Mancia G, Hua TA, Julius S, Weber MA, Coca A, Girerd X, Jamerson K, Larochelle P, Macdonald T, Schmieder RE, Anthony Schork M, Viskoper R, Widimsky J, Zanchetti A. Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial. Blood Pressure. 2008. doi:10.1080/08037050802169644 · PMID 18608200
29. Journal / agency Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. January 2010. doi:10.1136/bmj.b5465 · PMID 20068258 · PMC2806632
30. Other Novartis Annual Report 2010
31. Other Moeller P. Blockbuster Drugs That Will Go Generic Soon. 29 April 2011
32. Other Von Schaper E. Novartis's Jimenez Has Blockbuster Plans For Diovan After Patent Expires. 5 August 2011
33. Other Valsartan and hydrochlorothiazide Advanced Patient Information. 29 January 2024
34. Other Amlodipine and valsartan Advanced Patient Information. 27 June 2023
35. Other Amlodipine, valsartan, and hydrochlorothiazide Advanced Patient Information. 2 December 2023
36. Other Nebivolol and valsartan Advanced Patient Information. 14 October 2023
37. Other Sacubitril and Valsartan Monograph for Professionals. 7 November 2019
38. Journal / agency Exforge- amlodipine besylate and valsartan tablet, film coated. 12 June 2019
39. Journal / agency Diovan HCT- valsartan and hydrochlorothiazide tablet, film coated
40. Journal / agency Exforge HCT- amlodipine valsartan and hydrochlorothiazide tablet, film coated
41. Journal / agency Entresto- sacubitril and valsartan tablet, film coated. 1 September 2019
42. Journal / agency Fala L. Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure. American Health & Drug Benefits. September 2015. PMID 26557227 · PMC4636283
43. Journal / agency Khalil P, Kabbach G, Said S, Mukherjee D. Entresto, a New Panacea for Heart Failure?. Cardiovascular & Hematological Agents in Medicinal Chemistry. 2018. doi:10.2174/1871525716666180313121954 · PMID 29532764
44. Other Christensen J. Common heart drug recalled in 22 countries for possible cancer link
45. Other Edney A, Berfield S, Yu E. Carcinogens Have Infiltrated the Generic Drug Supply in the U.S. 12 September 2019
46. Other Several drugs containing valsartan being recalled due to contamination with a potential carcinogen. 9 July 2018
47. Other Valsartan Class Action
48. Other Nitrosamine impurities in medications: Guidance. 4 April 2022
49. Other Penjelasan BPOM RI Tentang Penarikan Obat Antihipertensi Yang Mengandung Zat Aktif Valsartan
50. Other Christensen J. FDA joins 22 countries' recall of common heart drug
51. Other Hong Kong health department issues recall for five heart drugs containing valsartan that was made in China. 20 July 2018
52. Journal / agency FDA updates on valsartan recalls. 2 August 2018
53. Journal / agency FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan, Losartan, and Irbesartan). 20 August 2018
54. Other Wendling P. More Drug Makers Tagged as Valsartan Recall Grows. 13 August 2018
55. Journal / agency FDA provides update on its ongoing investigation into valsartan products; and reports on the finding of an additional impurity identified in one firm's already recalled products. 13 September 2018
56. Other Harney A, Hirschler B. Toxin at heart of drug recall shows holes in medical safety net. 22 August 2018
57. Journal / agency Abdin AY, Yeboah P, Jacob C. Chemical Impurities: An Epistemological Riddle with Serious Side Effects. International Journal of Environmental Research and Public Health. February 2020. doi:10.3390/ijerph17031030 · PMID 32041209 · PMC7038150
58. Journal / agency ARB Recalls: Valsartan, Losartan and Irbesartan. 3 February 2020
59. Journal / agency Nitrosamine impurities. 23 October 2019
60. Journal / agency Control of Nitrosamine Impurities in Human Drugs. 24 February 2021
61. Other Clanton, Nancy. FDA OKs generic blood pressure drug in wake of recalls. 21 March 2019
62. Journal / agency Current and Resolved Drug Shortages and Discontinuations Reported to FDA U.S. Food and Drug Administration (FDA). Retrieved 13 July 2020
63. Other Lieferengpass Valsartan-CT 160mg. Gelbe Liste (in German). Pharmindex. Retrieved 13 July 2020

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.